~~<i id='D628F76DEB'><strike id='D628F76DEB'><tt id='D628F76DEB'><pre id='D628F76DEB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

fashion

author：comprehensive 2025-09-05 13:28:19 - browse：778

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： My superpower is killing ticks

hotspot

Wikipedia

focus

explore

focus

leisure time

VicePresidentKamalaHarrisstandsasHouseSpeakerMikeJohnsonofLouisianawatchesasPresidentBidendeliversth

WSS

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

First medicine developed to treat MASH expected to be approved soon

My superpower is killing ticks

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Former medical device CEO who sold dummy, plastic parts convicted of fraud

'Ancient DNA,' 23andMe reveal African American ancestries

entertainment

fashion

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

Attacks on the drug industry will lead to fewer breakthroughs

In age of alternative facts, a scholarly course on calling out crap

For BCIs, commercial hurdles may be bigger than scientific ones

BioMarin wins approval for gene therapy to treat hemophilia A

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Medicare proposal to cover medical devices draws a mixed reaction

Amylyx ALS drug fails large clinical trial

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Wikipedia

What the cancer research community can learn from the Covid response

Humana, CVS hope to turn members into patients at clinics

For BCIs, commercial hurdles may be bigger than scientific ones

Novo Nordisk obesity pill bests Wegovy in early trial

White House drug shortage group privately met with industry

OTC birth control: A brief history of over the counter pill design

focus

explore

focus

leisure time